Evidence map›Paper›PMID 20616783›Full record

ArticleJournal of visualized experiments : JoVE2010

Selection of aptamers for amyloid beta-protein, the causative agent of Alzheimer's disease.

Farid Rahimi, Gal Bitan

Open access · greenAbstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Aptamer and its applications in neurodegenerative diseases.Cellular and molecular life sciences : CMLS · 2017
    Review
  11. Aptamers as both drugs and drug-carriers.BioMed research international · 2014
    Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Farid RahimiDepartment of Neurology, David Geffen School of Medicine.
Gal Bitan
University of California, Los Angeles · US

Funding

Novel Specific Ligands for ABeta OligomersR21AG030709 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BITAN, GAL · 2007 to 2008
$357k
NIA NIH HHS AG030709NIA NIH HHS R21 AG030709
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive, age-dependent, neurodegenerative disorder with an insidious course that renders its presymptomatic diagnosis difficult(1). Definite AD diagnosis is achieved only postmortem, thus establishing presymptomatic, early diagnosis of AD is crucial for developing and administering effective therapies(2,3). Amyloid beta-protein (Abeta) is central to AD pathogenesis. Soluble, oligomeric Abeta assemblies are believed to affect neurotoxicity underlying synaptic dysfunction and neuron loss in AD(4,5). Various forms of soluble Abeta assemblies have been described, however, their interrelationships and relevance to AD etiology and pathogenesis are complex and not well understood(6). Specific molecular recognition tools may unravel the relationships amongst Abeta assemblies and facilitate detection and characterization of these assemblies early in the disease course before symptoms emerge. Molecular recognition commonly relies on antibodies. However, an alternative class of molecular recognition tools, aptamers, offers important advantages relative to antibodies(7,8). Aptamers are oligonucleotides generated by in-vitro selection: systematic evolution of ligands by exponential enrichment (SELEX)(9,10). SELEX is an iterative process that, similar to Darwinian evolution, allows selection, amplification, enrichment, and perpetuation of a property, e.g., avid, specific, ligand binding (aptamers) or catalytic activity (ribozymes and DNAzymes). Despite emergence of aptamers as tools in modern biotechnology and medicine(11), they have been underutilized in the amyloid field. Few RNA or ssDNA aptamers have been selected against various forms of prion proteins (PrP)(12-16). An RNA aptamer generated against recombinant bovine PrP was shown to recognize bovine PrP-beta(17), a soluble, oligomeric, beta-sheet-rich conformational variant of full-length PrP that forms amyloid fibrils(18). Aptamers generated using monomeric and several forms of fibrillar beta(2;)-microglobulin (beta(2;)m) were found to bind fibrils of certain other amyloidogenic proteins besides beta(2;)m fibrils(19). Ylera et al. described RNA aptamers selected against immobilized monomeric Abeta40(20). Unexpectedly, these aptamers bound fibrillar Abeta40. Altogether, these data raise several important questions. Why did aptamers selected against monomeric proteins recognize their polymeric forms? Could aptamers against monomeric and/or oligomeric forms of amyloidogenic proteins be obtained? To address these questions, we attempted to select aptamers for covalently-stabilized oligomeric Abeta40(21) generated using photo-induced cross-linking of unmodified proteins (PICUP)(22,23). Similar to previous findings(17,19,20), these aptamers reacted with fibrils of Abeta and several other amyloidogenic proteins likely recognizing a potentially common amyloid structural aptatope(21). Here, we present the SELEX methodology used in production of these aptamers(21).

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsAptamers, NucleotideCattleDNA, Single-StrandedHumansSELEX Aptamer TechniqueAmyloid beta-PeptidesAptamers, NucleotideDNA, Single-Stranded

Identifiers

PMID20616783
PMCPMC2918391
OpenAlexW2049348028

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.